Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

NCT00675441 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Terminated due to slow accrual.

Conditions

Graft-versus-Host Disease

Interventions

DRUG: Lenalidomide

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]